Latest Interviews
Showing 16–19 of 19 transcripts.
Clear all filters- Milken Institute1h 2m
Leaning In or Pushed Out: Where Are the Senior Women in Business?
Richard Ditizio, Margery Kraus, Sallie Krawcheck, Lauren Leichtman, Liz Claman, Marjorie Kraus, Michelle Kidley, Jeff, Manjuka Nariwala
Despite women comprising over half of college graduates, their representation in senior financial leadership remains stagnant at roughly 16%, a regression driven by systemic biases like the "intellectual honesty" trap and the double-bind of perceived aggression. Panelists highlighted that while diverse management teams generate over 30% higher returns, institutional inertia persists due to regressive maternity policies and a flexibility paradox that sidelines working mothers. To address this, experts recommend leveraging investor pressure through shareholder voting, utilizing regulatory CAMEL ratings to penalize homogenous boards, and fostering mandatory male inclusion to dismantle the status quo.
- Milken Institute1h 0m
Pensions: The Real Fiscal Cliff
Brad Belt, Jeff, Brian Pellegrino, Larry Schloss, David Vila
This analysis contrasts the severe underfunding of U.S. public and corporate pensions, highlighting Illinois's $100 billion shortfall against Wisconsin's successful hybrid model that achieves 99.8% funding. While New York City struggles with governance failures and outsourced management costs despite rising contributions, the corporate sector increasingly adopts Liability-Driven Investment strategies and benefit redesigns to mitigate insolvency risks. Ultimately, the report concludes that investment returns alone cannot resolve multi-trillion dollar deficits, necessitating structural reforms such as COLA adjustments or increased contributions to prevent taxpayer bailouts or state bankruptcy.
- Milken Institute1h 15m
The Promise of the Bioscience Century
Paul Irving, Mike Milken, Eric Cantor, Paul Chu, Jeff, Bernardo Zavala, Jr., Bernard Harris, Andy von Eschenbach, Peggy, Francis Collins, Chris Austin
This event analyzes the critical role of bioscience in driving global economic growth and societal well-being while highlighting China's aggressive $308 billion investment program that threatens to surpass U.S. leadership. Panelists discuss strategic institutional responses, such as DARPA's high-risk research model and the FDA's regulatory innovations, which have accelerated breakthroughs in prosthetics, personalized medicine, and disease prevention. However, fiscal constraints and shifting global demographics necessitate sustained bipartisan funding to preserve the United States' status as a central hub for scientific innovation and global health security.
- Milken Institute7 min
The Global Biomedical Industry: Preserving U.S. Leadership
The Milken Institute's latest report highlights the critical role of the U.S. biomedical sector, which supports over 5 million jobs but faces declining competitiveness due to outdated tax structures and shrinking domestic STEM enrollment. With the era of blockbuster drugs ending and rivals like China rapidly advancing in nanotechnology, the study argues that immediate policy reforms are essential to restore American leadership. Key recommendations include permanently enhancing the R&D tax credit by 25%, reducing the federal corporate tax rate to the advanced economy average of 23%, and increasing funding for the FDA and NIH to better accommodate personalized medicine frameworks.